A Study of BGM0504 in Chinese Patients With Type 2 Diabetes
NCT06974825 on ClinicalTrials.gov · last registry update 2025-05-16
Finished 13 August 2024, after enrolling 67 people. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 67
- Started
- 2023-08-30
- Primary completion
- 2024-08-13 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change From Baseline in Hemoglobin A1c (HbA1c)
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.